A daily pill version of semaglutide at a high dose (50 mg) helps people lose about 34 pounds in a year—just as much as the weekly injection.
Claim Context
Oral semaglutide at 50 mg daily results in a mean body weight reduction of 15.5 kg after 68 weeks in adults with obesity or overweight and comorbidities, a magnitude comparable to subcutaneous semaglutide 2.4 mg weekly, based on the OASIS 1 trial.
“OASIS 1: SMG achieved a significantly higher reduction in mean body weight (–15.5 kg and –15.1%) compared to placebo (−2.5 kg and –2.4%). At least a 5% weight reduction was achieved in 85% of those who received SMG, compared with only 26% in the placebo group.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
The comparative efficacy of oral semaglutide 50 mg versus subcutaneous semaglutide 2.4 mg on weight loss across all available RCTs.
A systematic review and meta-analysis of head-to-head RCTs comparing oral semaglutide 50 mg daily versus subcutaneous semaglutide 2.4 mg weekly in adults with BMI ≥30 kg/m², with weight change as primary outcome, including at least 3 trials with >1000 total participants and 68+ weeks of follow-up.
Causal equivalence or non-inferiority of oral semaglutide 50 mg versus subcutaneous semaglutide 2.4 mg for weight loss.
A double-blind, non-inferiority RCT of 600 adults with obesity, randomized 1:1 to oral semaglutide 50 mg daily or subcutaneous semaglutide 2.4 mg weekly, both with behavioral therapy, for 72 weeks, with primary outcome: percentage change in body weight measured by DXA.
Real-world weight loss outcomes and adherence patterns for oral semaglutide 50 mg compared to subcutaneous formulations in routine clinical practice.
A prospective cohort study of 1500 adults initiating either oral semaglutide 50 mg daily or subcutaneous semaglutide 2.4 mg weekly in primary care, tracking weight change, discontinuation rates, and gastrointestinal side effects over 2 years.
Association between oral semaglutide 50 mg use and reduced risk of weight regain compared to lower-dose oral formulations.
A matched case-control study comparing 300 adults who regained >10% of lost weight after 1 year on oral semaglutide 50 mg to 600 matched controls who maintained weight loss, assessing prior dose, duration, and adherence.
Prevalence of weight loss ≥10% among users of oral semaglutide 50 mg in a population at a single time point.
A cross-sectional survey of 5000 adults prescribed oral semaglutide 50 mg in community pharmacies, measuring current weight and duration of use to estimate proportion achieving ≥10% weight loss at time of survey.